Table 2 Baseline characteristics of NE and NE-PE group for matching cohort
Covariate | NE (n = 486) | NE-PE (n = 486) | P-value | SMD |
|---|---|---|---|---|
Age, year | 67.23 (15.95) | 67.44 (15.40) | 0.839 | 0.003 |
Gender, female, n (%) | 220 (45.5) | 217 (44.8) | 0.897 | 0.031 |
Weight, kg | 82.16 (26.92) | 83.29 (24.94) | 0.501 | 0.050 |
Ethnicity, n (%) | 0.734 | |||
White | 360 (74.1) | 354 (72.8) | 0.016 | |
Black | 40 (8.2) | 47 (9.7) | 0.007 | |
Other | 86 (17.7) | 85 (17.5) | 0.024 | |
Admission type, n (%) | 0.976 | |||
Emergency | 468 (96.3) | 467 (96.1) | 0.090 | |
Urgent | 8 (1.6) | 8 (1.6) | 0.050 | |
Elective | 10 (2.1) | 11 (2.3) | 0.074 | |
First careunit, n (%) | 0.709 | |||
MICU | 353 (72.6) | 354 (72.8) | 0.004 | |
SICU | 57 (11.7) | 50 (10.3) | 0.024 | |
Other | 76 (15.6) | 82 (16.9) | 0.016 | |
Vital signs | ||||
Heart rate, bmp | 95.59 (17.38) | 95.48 (17.10) | 0.927 | 0.034 |
Mean BP, mmHg | 70.95 (7.55) | 71.30 (8.28) | 0.489 | 0.012 |
Respiratory rate, bmp | 21.92 (4.73) | 21.87 (4.61) | 0.869 | 0.023 |
SpO2, % | 96.58 (3.71) | 96.48 (3.21) | 0.655 | 0.027 |
Temperature, °C | 36.84 (0.83) | 36.86 (0.78) | 0.725 | 0.022 |
SOFA score | 9.16 (3.61) | 9.11 (3.70) | 0.833 | 0.025 |
APS III | 70.88 (23.93) | 71.29 (22.85) | 0.789 | 0.027 |
Elixhauser comorbidity score | 14.56 (8.29) | 14.35 (8.59) | 0.695 | 0.013 |
Comorbidity | ||||
Congestive heart failure, n (%) | 225 (46.5) | 209 (43.2) | 0.332 | 0.004 |
Cardiac arrhythmias, n (%) | 249 (51.4) | 239 (49.4) | 0.563 | 0.010 |
Pulmonary circulation disorder, n (%) | 48 (9.9) | 47 (9.7) | 1.000 | 0.003 |
Peripheral vascular disorder, n (%) | 43 (8.9) | 47 (9.7) | 0.740 | 0.003 |
Neurological diseases, n (%) | 56 (11.6) | 66 (13.6) | 0.383 | 0.024 |
Chronic pulmonary disease, n (%) | 127 (26.2) | 130 (26.9) | 0.884 | 0.005 |
Hypertension, n (%) | 247 (51.0) | 246 (50.8) | 1.000 | 0.010 |
Diabetes, n (%) | 164 (33.9) | 161 (33.3) | 0.892 | 0.009 |
Renal failure, n (%) | 126 (26.0) | 122 (25.2) | 0.825 | 0.010 |
Liver disease, n (%) | 123 (25.4) | 120 (24.8) | 0.882 | 0.007 |
Metastatic cancer, n (%) | 38 (7.9) | 37 (7.6) | 1.000 | 0.020 |
Solid tumor without metastasis, n (%) | 19 (3.9) | 17 (3.5) | 0.865 | 0.020 |
Fluid and electrolyte disorders, n (%) | 288 (59.5) | 289 (59.7) | 1.000 | 0.034 |
Drug abuse, n (%) | 18 (3.7) | 15 (3.1) | 0.723 | 0.000 |
Alcohol abuse, n (%) | 48 (9.9) | 47 (9.7) | 1.000 | 0.043 |
Laboratory tests | ||||
WBC, k/uL | 18.67 (11.95) | 18.64 (11.99) | 0.967 | 0.032 |
Hemoglobin, g/dL | 9.60 (1.85) | 9.64 (1.91) | 0.745 | 0.017 |
Platelet, k/uL | 189.31 (130.94) | 190.31 (130.87) | 0.905 | 0.043 |
Bilirubin, mg/dL | 2.69 (5.50) | 2.55 (4.65) | 0.652 | 0.016 |
Serum creatinine, n (%) | 0.733 | |||
< 1 mg/dL | 86 (17.7) | 78 (16.0) | 0.000 | |
≥ 1, < 2 mg/dL | 172 (35.4) | 181 (37.2) | 0.009 | |
≥ 2 mg/dL | 228 (46.9) | 227 (46.7) | 0.008 | |
Urea nitrogen, n (%) | 0.901 | |||
< 20 mg/dL | 79 (16.3) | 84 (17.3) | 0.017 | |
≥ 20, < 40 mg/dL | 182 (37.4) | 182 (37.4) | 0.019 | |
≥ 40 mg/dL | 225 (46.3) | 220 (45.3) | 0.031 | |
Glucose, mg/dl | 149.04 (49.06) | 149.63 (51.74) | 0.856 | 0.022 |
Lactate, mmol/L | 4.11 (3.11) | 4.22 (3.22) | 0.563 | 0.038 |
Bicarbonate, mmol/L | 18.21 (5.45) | 18.38 (5.69) | 0.628 | 0.022 |
INR | 2.18 (1.94) | 2.19 (1.84) | 0.943 | 0.064 |
Potassium, mmol/L | 4.83 (1.06) | 4.86 (0.96) | 0.690 | 0.023 |
Sodium, mmol/L | 140.43 (5.93) | 140.43 (6.82) | 0.996 | 0.014 |
Urine output firstday, ml | 1280.48 (1078.06) | 1290.24 (1126.80) | 0.891 | 0.018 |
Mechanical ventilation firstday, n (%) | 341 (70.5) | 333 (68.8) | 0.625 | 0.026 |
RRT firstday, n (%) | 52 (10.7) | 53 (11.0) | 1.000 | 0.009 |
Vasopressin, n (%) | 212 (43.8) | 225 (46.5) | 0.438 | 0.068 |
Dopamine, n (%) | 97 (20.0) | 96 (19.8) | 1.000 | 0.000 |
Dobutamine, n (%) | 36 (7.4) | 41 (8.5) | 0.635 | 0.004 |
Epinephrine, n (%) | 7 (1.4) | 17 (3.5) | 0.063 | 0.064 |
Microorganism, n (%) | 417 (86.2) | 407 (84.1) | 0.416 | 0.012 |
Initial NE dose, ug/kg.min | 0.12 (0.11) | 0.13 (0.14) | 0.168 | 0.035 |